Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab

PURPOSE: To assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (). EXPERIMENTAL DESIGN: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Joseph, Richard W., Elassaiss-Schaap, Jeroen, Kefford, Richard, Hwu, Wen-Jen, Wolchok, Jedd D., Joshua, Anthony M., Ribas, Antoni, Hodi, F. Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Dronca, Roxana, Hersey, Peter, Weber, Jeffrey S., Patnaik, Amita, de Alwis, Dinesh P., Perrone, Andrea, Zhang, Jin, Kang, S. Peter, Ebbinghaus, Scot, Anderson, Keaven M., Gangadhar, Tara C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916264/
https://ncbi.nlm.nih.gov/pubmed/29685882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2386
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller